Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 11:28 AM ET


Company Overview of Sigma-Tau Pharmaceuticals, Inc.

Company Overview

Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company that focuses on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases in Canada. The company develops prescription pharmaceuticals, including Cystaran, a cysteamine ophthalmic solution; Carnitor levocarnitine tablets, oral solution, sugar-free oral solution, and injection; Carnitor, a levocarnitine injection; Matulane procarbazine hydrochloride capsules; Adagen, a pegademase bovine; Abelcet, an amphotericin B lipid complex injection; and DepoCyt, a cytarabine liposome injection. It also develops nonprescription medicines and dietary supplements. The company was foun...

9841 Washingtonian Boulevard

Suite 500

Gaithersburg, MD 20878

United States

Founded in 1980





Key Executives for Sigma-Tau Pharmaceuticals, Inc.

Chief Executive Officer
Vice President of Finance
Chief Executive Officer of Sigma-Tau Group
Vice President of Medical Affairs
Vice President of Clinical Affairs
Age: 59
Compensation as of Fiscal Year 2015.

Sigma-Tau Pharmaceuticals, Inc. Key Developments

Sigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis

Sigma-Tau Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for the company's investigational compound, STP-206 (lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis), a live biotherapeutic being developed for the prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1,500 grams. The company is currently conducting a multi-center, double-blind, randomized, placebo-controlled Phase 1b/2a clinical trial for STP-206 at a number of different sites in the United States. An Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the beneficiary company with a seven-year period of U.S. marketing exclusivity if it is the first product to reach marketing approval, as well as potential tax credits for clinical research costs, federal grants, and a waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

Sigma-Tau Pharmaceuticals Names Dave Lemus as Chief Executive

Sigma-Tau Pharmaceuticals appointed Dave Lemus as chief executive.

Sigma-Tau Pharmaceuticals, Inc. Signs License Agreement with Crosscare Limited

Sigma-Tau Pharmaceuticals, Inc. announced that it has signed an exclusive United States license agreement with Crosscare Limited to market and distribute Colief Infant Drops for the treatment of colic. Under the multi-year license agreement, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the United States.

Similar Private Companies By Industry

Company Name Region
TOLMAR Therapeutics, Inc. United States
Areva Pharmaceuticals Inc. United States
A. M. Todd Botanical Therapeutics, LLC United States
Essentialis, Inc. United States
Heritage Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sigma-Tau Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at